Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab for Prophylaxis of Gout Flares During Allopurinol Initiation
NCT00819585Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2008
- Primary completion
- Aug 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 2 trial of canakinumab in gout, sponsored by Novartis. Started Dec 2008; status: completed.
02
Drugs
canakinumab
03
Conditions
gout
Beyond the preview
Go deeper on NCT00819585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00819585.